Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-04-23
2009-11-17
Shukla, Ram R (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388220
Reexamination Certificate
active
07619070
ABSTRACT:
Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5886153 (1999-03-01), Mogensen et al.
patent: 5919453 (1999-07-01), Benoit et al.
patent: 6787634 (2004-09-01), Benoit et al.
patent: 2002/0055492 (2002-05-01), Benoit et al.
patent: 0 563 487 (1993-10-01), None
patent: WO 9007861 (1990-07-01), None
patent: WO-95/07716 (1995-03-01), None
patent: WO 9852976 (1998-11-01), None
patent: WO-01/54721 (2001-08-01), None
patent: WO-01/55215 (2001-08-01), None
Janeway et al., Immunobiology, p. 3.2, Garland Publishing, New York, 1997.
Rudikoff, et al. Proc. Natl. Acad. Sci. USA 79: 1979-83 (1982).
Wu et al., J. Mol. Biol. 294: 151-162 (1999).
Paul, Fundamental Immunology, 3rdEd., pp. 292-295, Raven Press, New York, 1993.
Reff et al., Crit. Rev. Oncol. Hematol. 40: 25-35 (2001).
MacCallum et al, J. Mol. Biol., 262,732-745, 1996.
Brown et al., J Immunol. May 1, 1996;156(9):3285-91.
Casset et al, Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Mateo et al., Hybridoma. Dec. 2000;19(6):463-71.
Deavin et al., Mol Immunol. Feb. 1996;33(2):145-55.
Janeway et al., Immunobiology, 5th Ed., Garland Science, pp. 116-117 (2001).
Vajdos et al., J Mol Biol. Jul. 5, 2002;320(2):415-28.
Colman P. M., Research in Immunology, 145:33-36, 1994.
Amin et al., Innovations in Pharmaceutical Technology, Samedan Ltd, publishers, Jun. 2002.
O'Brien et al., Humanization of Monoclonal Antibodies by CDR Grafting, Methods in Molecular Biology, Humana Press, 2003, pp. 81-100.
The Declaration under 37 C.F.R. § 1.132 of Dr. Michael G. Tovey, May 9, 2002, pp. 1-8 published in conjunction with the publication of US 20020055492.
Aguet et al., “Interferon 5” Ed. I. Gresser p. 1-22, Academic Press, London 1983.
Arvin and Miller, Arthritis Rheum. 1984;27:582-585.
Brinkmann et al., J. Exp. Med., 1993;178:1655-1663.
Cook et al., J. Biol. Chem. 1996;271:13448-13453.
Cutrone and Langer, J. Biol. Chem. 2001;276:17140-17148.
Finkelman et al., J. Exp. Med. 1991;174:1179-1188.
Foulis et al., Lancet. 1987;2:1423-1427.
Haller et al., J. Exp. Med. 1981;154:199-203.
Hardy et al., Blood. 2001;97:473-482.
Hertzog et al., Clin Immunol. Immunopath. 1988;48:192-201.
Hooks et al., Arthritis Theum/ 1982;25:396-400.
Hopkins and Meager, Clin. Exp. Immunol. 1988;73:88-92.
Lewerenz et al., J. Mol. Biol. 1998;282:585-599.
Lindenmann et al., Methods Enzymol. 1981;78:181-188.
Luft et al., J. Immunol. 1998;161:1947-1953.
Luft et al., Int. Immunol. 2002;14:367-380.
Radvanyi et al., Scan. J. Immunol. 1999+:50:499-509.
Santini et al., J. Exp. Med. 2000;191:17771788.
Streuli et al., PNAS-USA. 1981;78:2848-2852.
Tough et al., Science. 1996;272:1947-1950.
Benoit et al., “A Monoclonal Antibody to Recombinant Human IFN-α Receptor Inhibits Biologic Activity of Several Species of Human IFN- α, IFN-β, and IFN-Ω. Detection of Heterogeneity of the Cellular Type I IFN Receptor,”Journal of Immunology, 150:707-716 (1993).
Blanco et al., “Induction of Dendritic Cell Differentiation by IFN- α in Systemic Lupus Erythematosus,” Science,American Association for the Advancement of Science, 294:1540-1543 (2001).
Corssmit et al., “Effects of Interferon-α (INF-α) Administration on Leucocytes in Healthy Humans,”Clinical and Experimental Immunology, 107:359-363 (1997).
Eid et al., “Localization of a Receptor Nonapeptide with a Possible Role in the Bindign of the Type I Interferons,”European Cytokine Network, 11:560-573 (2000).
Tilg et al., “Interferon-α Induces Circulating Tumor Necrosis Factor Receptor p55 in Humans,”Blood, 85:433-435 (1995).
Winter et al., “Humanized Antibodies,”Trends in Pharmacological Sciences, 14:139-143 (1993).
Soderlind et al., “The immune diversity in a test tube—non-immunised antibody libraries and functional variability in defined protein scaffolds,” Comb Chem High Throughput Screen. Aug. 2001;4(5):409-16.
Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” Br J Cancer. Jul. 2000;83(2):252-60.
Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling,” Biotechnology (N Y). Jul. 1992;10(7):779-83.
Rader et al., “A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries,” Proc Natl Acad Sci U S A. Jul. 21, 1998;95(15):8910-5.
Yang et al., “CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range,” J Mol Biol. Dec. 1, 1995;254(3):392-403.
Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proc Natl Acad Sci U S A. Apr 26, 1994;91(9):3809-13.
Wu et al., “Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb,” Proc Natl Acad Sci U S A. May 26, 1998;95(11):6037-42.
Mogensen, et al., “The Type I Interferon Receptor: Structure, Function and Evolution of a Family Business,”J. of Interferon and Cytokine Research(1999); 19: 1069-1098.
Kettleborough, et al., “Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation,”Protein Engineering(1991); 4(7): 773-783.
Benoit, et al., A Monoclonal Antibody to Recombinant Human INF-α Receptor Inhibits Biologic Activity of Several Species of Human IFN-α, IFN-β, and IFN-ω, J Immunology, 150(3):707-716 (1993).
Eid et al., “Characterization of a Domain of Human Type I Interferon Receptor Protein Involved in Ligand Binding”, J. Interferon Cytokine Research, 15:205-211 (1995).
Bebbington Christopher R.
Cardarelli Josephine M.
Carr Francis J.
Chen Tseng-Hui Timothy
King David J.
Baker & Botts L.L.P.
Medarex Inc.
Shukla Ram R
Skelding Zachary
LandOfFree
Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies to interferon alpha receptor-1 (IFNAR-1), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122481